Abstract:Allergen specific immunotherapy (SIT) is believed the only causative treatment that could change the progress of asthma. The mechanisms of SIT are complex, including the very early desensitization effects, modulation of T and B cell responses and related antibody isotypes, and migration of eosinophils, basophils, and mast cells to tissues, as well as release of their mediators. Basic studies have shown that immunotherapy works mainly through expanding allergen-specific Th1 immunity and suppressing the Th2 responses resulting from clinical observation. Treg cells are considered play key roles in modulating the switch from Th2 cells to Th0 or Th1 cells, through cytokine IL-10 and TGF-β, as well as the switch from production of IgE to blocking antibody IgG4 isotype. The clinical practice over 100 years demonstrated its unique advantage over the first line medicine inhaled corticosteroid. It has dual functions including causative and preventative therapy. It can significantly reduce the symptom score and airway hyperresponsiveness in asthmatic patients. Furthermore, its salutary effects continue for years after the completion of treatment course. Based on the administration route, conventional subcutaneous specific immunotherapy (SCIT) and sublingual specific immunotherapy (SLIT) are the most popular methods used in clinical work. However, new administration methods such as intralymphatic immunotherapy and epicutaneous allergen- specific immunotherapy are under active clinical trials. The future studies of immunotherapy will focus on the alternative therapy with modified extract to provide the least side effects and the best clinical efficacies.Allergen specific immunotherapy (SIT), also called desensitization or hyposensitization, is the repeated administration of allergen vaccines to allergic individuals in order to provide long term relief of symptoms and improvement in quality of life during subsequent natural allergen exposure (Bousquet et al., 1998).Bronchial asthma is considered a type I allergic reaction characterized by Th2 cells domination and allergen specific IgE mediation. The immunotherapy targeting at the allergic reaction is the optimal treatment. Clinical trials showed though inhaled gluccocorticoid could control the symptoms of asthma, it could not block the inflammation of airway (Guilbert et al., 2006). However, SIT not only improves the clinical symptoms with reduced symptom score and medication, but also has long-term effect and prevents the progress of inflammation. Thus SIT is believed the only causative treatment that could change the progress of asthma. The current chapter focuses on the mechanism of SIT and its clinical practice.

Clostridium Butyricum in Combination with Specific Immunotherapy Converts Antigen-Specific B Cells to Regulatory B Cells in Asthmatic Patients.

Generation of IgE-specific Cytotoxic T Lymphocytes As a Novel Immunotherapeutic Approach for the Treatment of Allergic Asthma.

Induction Of Cd4(+)Cd25(+)Foxp3(+)Il-10(+) T Cells In Hdm-Allergic Asthmatic Children With Or Without Sit

Altered Frequency of NK Cells and Treg Cells by <i>Astragalus</i> Polysaccharide Combined with Budesonide in Asthma Model Mice

Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Bifidobacterium animalis subsp. lactis CCFM1274 relieved allergic asthma symptoms by modifying intestinal tryptophan metabolism in mice

Immunotherapy of Asthma: from Basic Research to Clinical Practices

Specific immunotherapy for bronchial asthma

ICS/LABA Combined With Subcutaneous Immunotherapy Modulates the Th17/Treg Imbalance in Asthmatic Children

Effect and mechanism of allergen‐specific immunotherapy on small airway dysfunction in children with asthma

Effect of Specific Immunotherapy on the Expression of NKT Cells in House Dust Mite Extracts-Sensitized Murine Model

Clostridium leptum induces the generation of interleukin-10+ regulatory B cells to alleviate airway inflammation in asthma

Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate

Short-Chain Fatty Acids Promote Immunotherapy by Modulating Immune Regulatory Property in B Cells

The effect of specific immunotherapy on natural killer T cells in peripheral blood of house dust mite-sensitized children with asthma.

Effect of immunotherapy with purified pollen allergens

Efficacy of Sublingual Immunotherapy for Allergic Asthma: Retrospective Meta-Analysis of Randomized, Double-Blind and Placebo-Controlled Trials

Alteration of lung tissues proteins in birch pollen induced asthma mice before and after SCIT

Aerosol Inhalation of Heat-Killed Clostridium butyricum CGMCC0313-1 Alleviates Allergic Airway Inflammation in Mice

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Dust mite-derived Enterobacterial fimbriae H protein enforces the allergen specific immunotherapy in asthma mice